SIETES :: 92833 citas

Resultados de la búsqueda por ANTECEDENTES REFINAR BÚSQUEDA

1.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

2.

Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and management of penicillin allergy. A review. JAMA 2019;321:15 de enero. [Ref.ID 103008]

3.

Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540-7. [Ref.ID 100280]

4.

Anónimo. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). U.S. Food and Drug Administration 2015:30 de marzo. [Ref.ID 98888]

5.

Anónimo. New oral anticoagulants apixaban (Eliquis), dabigatran (Pradaxa) and rivaroxaban (Xarelto): risk of serious haemorrhage - clarified contraindications apply to all three medicines. Drug Safety Update 2013;7:octubre. [Ref.ID 96225]

6.

Macy E, Ngor EW. Safely diagnosing clinically significant penicillin allergy using only penicilloyl-polylysine, penicillin, and oral amoxicillin. J Allergy Clin Immunol 2013;1:258-63. [Ref.ID 95645]

7.

Tebé C, Miquel del Río L, Di Gregorio S, Casas L, Estrada M-D, Kotzeva A, Espallargues M. Validació del model predictiu de fractura major osteoporòtica FRAX en una cohort històrica de dones espanyoles. Annals Med (Barc) 2012;95:169-74. [Ref.ID 93265]

8.

Anónimo. Febuxostat (Adenuric) stop treatment signs or symptoms of serious hypersensitivity (eg. serious skin reactions or systemic hypersensitivity) occur. Drug Safety Update 2012;5:junio. [Ref.ID 92646]

9.

Anónimo. FDA issues cautions on use of fingolimod in MS patients with heart, stroke problems.. DIA Daily 2012:15 de mayo. [Ref.ID 92625]

10.

Gillison ML, Broutian T, Pickard RKL, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307:693-703. [Ref.ID 92368]

11.

Stein CM, Ray WA. The ethics of placebo in studies with fracture end points in osteoporosis. N Engl J Med 2010;363:1367-70. [Ref.ID 89434]

12.

Rosen CJ, Khosla S. Placebo-controlled trials in osteoporosis - Proceeding with caution. N Engl J Med 2010;363:1365-7. [Ref.ID 89433]

13.

Pearce SHS, Cheetham TD. Diagnosis and management of vitamin D deficiency. BMJ 2010;340:142-7. [Ref.ID 87640]

14.

Sahota O. Reducing the risk of fractures with calcium and vitamin D. BMJ 2010;340:109-11. [Ref.ID 87576]

15.

The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010;340:139. [Ref.ID 87575]

16.

Colón-Emeric CS, Lyles KW. Should there be a fracas over FRAX and other fracture prediction tools?. Arch Intern Med 2009;169:2095. [Ref.ID 87416]

17.

Ensrud KE, Lui L-Y, Taylor BC, Schousboe JT, Donaldson MG, Fink HA, Cauley JA, Hillier TA, Browner WS, Cummings SR, for the Study of Osteoporotic Fractures Research Group. A comparison of prediction models for fractures in older women. Is more better?. Arch Intern Med 2009;169:2087-94. [Ref.ID 87415]

18.

Cimbollek S, Quiralte J, Avila R. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs. N Engl J Med 2009;361:2197-8. [Ref.ID 87216]

19.

Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:1015. [Ref.ID 86994]

20.

Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008;371:923-31. [Ref.ID 82403]